Advertisement

Disease Assessment in Behçet Syndrome

  • Gonca Mumcu
  • Yusuf Yazici
  • Gulen Hatemi
Chapter

Abstract

Behçet syndrome (BS) starts early and may last a long time so that the whole of the working life and the family can be compromised by the disease process. A few disease assessment measures have been studied in BS. The ones that have been developed specifically for BS are small in number, and most lack coverage for some manifestations of the disease, which may be seen with different frequencies in different parts of the world, such as gastrointestinal and neurological involvement. Eye involvement, the main cause of morbidity, still lacks good and easy to use assessment tools, while  new tools are available for the assessment of skin and mucosa involvement. Efforts are ongoing for developing a validated Core Set of Outcome Measures for BS.

Keywords

Behçet syndrome Disease activity Indices Measurement Oral health Quality of life 

References

  1. 1.
    Sut N, Seyahi E, Yurdakul S, Senocak M, Yazici H. A cost analysis of Behçet’s syndrome in Turkey. Rheumatology (Oxford). 2007;46:678–82.CrossRefGoogle Scholar
  2. 2.
    Watt RG. Strategies and approaches in oral disease prevention and health promotion. Bull World Health Organ. 2005;83:711–8.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Nelson EC, Eftimovska E, Lind C, Hager A, Wasson JH, Lindblad S. Patient reported outcome measures in practice. BMJ. 2015;350:g7818.PubMedCrossRefGoogle Scholar
  4. 4.
    Deshpande PR, Rajan S, Sudeepthi BL, Abdul Nazir CP. Patient-reported outcomes: a new era in clinical research. Perspect Clin Res. 2011;2(4):137–44.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Ni Riordain R, Shirlaw P, Alajbeg I, Al Zamel GY, Fung PL, Yuan AD, et al. World Workshop on Oral Medicine VI: patient-reported outcome measures and oral mucosal disease: current status and future direction. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;120(2):152–60. e111PubMedCrossRefGoogle Scholar
  6. 6.
    Mumcu G, Alibaz-Oner F, Oner SY, Ozen G, Atagunduz P, Inanc N, et al. Oral ulcer activity in Behcet’s disease: poor medication adherence is an underestimated risk factor. Eur J Rheumatol. 2017;4(2):109–12.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Hatemi G, Merkel PA, Hamuryudan V, Boers M, Direskeneli H, Aydin SZ, et al. Outcome measures used in clinical trials for Behçet syndrome: a systematic review. J Rheumatol. 2014;41:599–612.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Prevoo ML, Van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Yazici H, Tuzun Y, Pazarli H, Yurdakul S, Ozyazgan Y, Ozdogan H, et al. Influence of age of onset and patient’s sex on the prevalence and severity of manifestations of Behçet’s syndrome. Ann Rheum Dis. 1984;43:783–9.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Lawton G, Bhakta BB, Chamberlain MA, Tennant A. The Behçet’s disease activity index. Rheumatology (Oxford). 2004;43:73–8.CrossRefGoogle Scholar
  11. 11.
    Beaton DE. Understanding the relevance of measured change through studies of responsiveness. Spine. 2000;25:3192–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Lee ES, Kim HS, Bang D, Yu HG, Chung H, Shin DH, et al. Development of clinical activity form for Korean patients with Behçet’s disease. Adv Exp Med Biol. 2003;528:153–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Neves FS, Moraes JC, Kowalski SC, Goldenstein-Schainberg C, Lage LV, Gonçalves CR. Cross-cultural adaptation of the Behçet’s Disease Current Activity Form (BDCAF) to Brazilian Portuguese language. Clin Rheumatol. 2007;26:1263–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Hamuryudan V, Fresko I, Direskeneli H, Tenant MJ, Yurdakul S, Akoglu T, Yazici H. Evaluation of the Turkish translation of a disease activity form for Behçet’s syndrome. Rheumatology (Oxford). 1999;38:734–6.CrossRefGoogle Scholar
  15. 15.
    Forbess C, Swearingen C, Yazici Y. Behçet’s Syndrome Activity Score (BSAS): a new disease activity assessment tool, composed of patient-derived measures only, is strongly correlated with The Behçet’s Disease Current Activity Form (BDCAF). Ann Rheum Dis. 2008;67(SII):360.Google Scholar
  16. 16.
    Shahram F, Khabbazi A, Nadji A, Ziaie N, Banihashemi AT, Davatchi F. Comparison of existing disease activity indices in the follow-up of patients with Behçet’s disease. Mod Rheumatol. 2009;19(5):536–41.PubMedCrossRefGoogle Scholar
  17. 17.
    Simsek I, Meric C, Erdem H, Pay S, Kilic S, Dinc A. Accuracy of recall of the items included in disease activity forms of Behçet’s disease: comparison of retrospective questionnaires with a daily telephone interview. Clin Rheumatol. 2008;27:1255–60.PubMedCrossRefGoogle Scholar
  18. 18.
    Bang D, Kim HS, Lee ES, Lee S. The significance of laboratory test in evaluating the clinical activity of Behçet’s disease. In: Proceedings of the 9th international conference in Behçet’s disease held in Seoul, Korea, 27–29 May; 2000.Google Scholar
  19. 19.
    Deuter CME, Kotter I, Gunaydin I, Zierhut M, Stubiger N. Ocular involvement in Behçet’s disease: first 5-year-results for visual development after treatment with interferon alfa-2a. Ophthalmologe. 2004;101:129–34.PubMedCrossRefGoogle Scholar
  20. 20.
    Amberger M, Groll S, Günaydin I, Deuter C, Vonthein R, Kötter I. Intracellular cytokine patterns in Behçet’s disease in comparison to ankylosing spondylitis – influence of treatment with interferon-alpha2a. Clin Exp Rheumatol. 2007;25(Suppl 45):S52–7.PubMedGoogle Scholar
  21. 21.
    Kötter I, Koch S, Vonthein R, Rückwaldt U, Amberger M, Günaydin I, et al. Cytokines, cytokine antagonists and soluble adhesion molecules in patients with ocular Behçet’s disease treated with human recombinant interferon-alpha2a. Results of an open study and review of the literature. Clin Exp Rheumatol. 2005;23(Suppl 38):S20–6.PubMedGoogle Scholar
  22. 22.
    Cekmen M, Evereklioglu C, Er H, Inaloz HS, Doganay S, Yurkoz Y, Ozerol IH. Vascular endothelial growth factor levels are increased and associated with disease activity in patients with Behçet’s syndrome. Int J Dermatol. 2003;42(11):870–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Nanke Y, Kotake S, Goto M, Ujihara H, Matsubara M, Kamatani N. Decreased percentages of regulatory T cells in peripheral blood of patients with Behçet’s disease before ocular attack: a possible predictive marker of ocular attack. Mod Rheumatol. 2008;18(4):354–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Pay S, Abbasov T, Erdem H, Musabak U, Simsek I, Pekel A, et al. Serum MMP-2 and MMP-9 in patients with Behçet’s disease: do their higher levels correlate to vasculo-Behçet’s disease associated with aneurysm formation? Clin Exp Rheumatol. 2007;25(Suppl 45):S-70–5.Google Scholar
  25. 25.
    Kim DH, Park Y, Kim B, Kim SW, Park SJ, Hong SP, et al. Fecal calprotectin as a non-invasive biomarker for intestinal involvement of Behçet’s disease. J Gastroenterol Hepatol. 2017;32(3):595–601.PubMedCrossRefGoogle Scholar
  26. 26.
    Esatoglu SN, Hatemi I, Ozguler Y, Hatemi G, Uzun H, Celik AF, Yazici H. Faecal but not serum calprotectin levels look promising in predicting active disease in Behçet’s syndrome patients with gastrointestinal involvement. Clin Exp Rheumatol. 2018;36(6 Suppl 115):90–6.PubMedGoogle Scholar
  27. 27.
    Tugal-Tutkun I, Herbort CP, Khairallah M. The Angiography Scoring for Uveitis Working Group (ASUWOG). Scoring of dual fluorescein and ICG inflammatory angiographic signs for the grading of posterior segment inflammation (dual fluorescein and ICG angiographic scoring system for uveitis). Int Ophthalmol. 2010;30(5):539–52.PubMedCrossRefGoogle Scholar
  28. 28.
    Kaburaki T, Namba K, Sonoda KH, Kezuka T, Keino H, Fukuhara T, et al. Behçet’s disease ocular attack score 24: evaluation of ocular disease activity before and after initiation of infliximab. Jpn J Ophthalmol. 2014;58(2):120–30.PubMedCrossRefGoogle Scholar
  29. 29.
    Tugal-Tutkun I, Cingu K, Kir N, et al. Use of laser flare-cell photometry to quantify intraocular inflammation in patients with Behçet’s uveitis. Graefes Arch Clin Exp Ophthalmol. 2008;246:1169–77.PubMedCrossRefGoogle Scholar
  30. 30.
    Yalcindag FN, Bingol Kiziltunc P, Savku E. Evaluation of intraocular inflammation with laser flare photometry in Behçet uveitis. Ocul Immunol Inflamm. 2017;25:41–5.PubMedCrossRefGoogle Scholar
  31. 31.
    Mesquida M, Llorenç V, Fontenla JR, et al. Use of ultrawide-field retinal imaging in the management of active Behçet retinal vasculitis. Retina. 2014;34:2121–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Moon SW, Kim BH, Park UC, Yu HG. Inter-observer variability in scoring ultra-wide-field fluorescein angiography in patients with Behçet retinal vasculitis. Ocul Immunol Inflamm. 2017;25(1):20–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Nussenblatt RB, Pelestine AG, Chan CC, et al. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 1985;92:467–71.PubMedCrossRefGoogle Scholar
  34. 34.
    Davis JL, Madow B, Cornett J, et al. Scale for photographic grading of vitreous haze in uveitis. Am J Ophthalmol. 2010;150:637–41.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Ozyazgan Y, Ucar D, Erdogan M, Ozguler Y, Hatemi G, Yurdakul S, et al. Factors associated with damage progression in Behçet’s syndrome uveitis. Arthritis Rheumatol. 2018;70(suppl 10)Google Scholar
  36. 36.
    Mumcu G, Inanc N, Taze A, Ergun T, Direskeneli H. A new mucocutaneous activity index for Behcet’s disease. Clin Exp Rheumatol. 2014;32(4 Suppl 84):S8–6.Google Scholar
  37. 37.
    Mumcu G, Sur H, Inanc N, Karacayli U, Cimilli H, Sisman N, et al. A composite index for determining the impact of oral ulcer activity in Behcet’s disease and recurrent aphthous stomatitis. J Oral Pathol Med. 2009;38(10):785–91.CrossRefGoogle Scholar
  38. 38.
    Senusi A, Higgins S, Fortune F. The influence of oral health and psycho-social well-being on clinical outcomes in Behcet’s disease. Rheumatol Int. 2018;38(10):1873–83.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Mumcu G, Inanc N, Ergun T, Ikiz K, Gunes M, Islek U, et al. Oral health related quality of life ıs affected by disease activity ın Behçet’s disease. Oral Dis. 2006;12:145–51.PubMedCrossRefGoogle Scholar
  40. 40.
    Mumcu G, Niazi S, Stewart J, Hagi-Pavli E, Gokani B, Seoudi N, et al. Oral health and related quality of life status in patients from UK and Turkey: a comparative study in Behçet’s disease. J Oral Pathol Med. 2009;38:406–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Sogur E, Onem E, Kalfa M, Emmungil H, Bostanci N, Aksu K, et al. Oral health and oral quality of life in inactive patients with familial Mediterranean fever without amyloidosis. Clin Exp Rheumatol. 2013;31(3 Suppl 77):15–9.PubMedGoogle Scholar
  42. 42.
    Mumcu G, Hayran O, Ozalp DO, Inanc N, Yavuz S, Ergun T, Direskeneli H. The assessment of oral health related quality of life by factor analysis in patients with Behçet’s disease and recurrent apthous stomatitis. J Oral Pathol Med. 2007;36:147–52.PubMedCrossRefGoogle Scholar
  43. 43.
    Hayran O, Mumcu G, Inanc N, Ergun T, Direskeneli H. Assessment of minimal clinically important improvement by using Oral Health Impact Profile-14 in Behcet’s disease. Clin Exp Rheumatol. 2009;27(2 Suppl 53):S79–84.PubMedGoogle Scholar
  44. 44.
    Mumcu G. Behcet’s disease: a dentist’s overview. Clin Exp Rheumatol. 2008;26(4 Suppl 50):S121–4.PubMedGoogle Scholar
  45. 45.
    Alibaz-Oner F, Mumcu G, Kubilay Z, Ozen G, Celik G, Karadeniz A, Can M, Oner SY, Inanc N, Atagunduz P, Ergun T, Direskeneli H. Unmet need in Behcet’s disease: most patients in routine follow-up continue to have oral ulcers. Clin Rheumatol. 2014;33(12):1773–6.PubMedCrossRefGoogle Scholar
  46. 46.
    Coit P, Mumcu G, Ture-Ozdemir F, Unal AU, Alpar U, Bostanci N, et al. Sequencing of 16S rRNA reveals a distinct salivary microbiome signature in Behcet’s disease. Clin Immunol. 2016;169:28–35.PubMedCrossRefGoogle Scholar
  47. 47.
    Mumcu G, Cimilli H, Karacayli U, Inanc N, Ture-Ozdemir F, Eksioglu-Demiralp E, et al. Salivary levels of HNP 1-3 are related to oral ulcer activity in Behcet’s disease. Int J Dermatol. 2013;52(10):1198–201.PubMedGoogle Scholar
  48. 48.
    Karacayli U, Mumcu G, Simsek I, Pay S, Kose O, Erdem H, et al. The close association between dental and periodontal treatments and oral ulcer course in behcet’s disease: a prospective clinical study. J Oral Pathol Med. 2009;38(5):410–5.PubMedCrossRefGoogle Scholar
  49. 49.
    Senusi A, Seoudi N, Bergmeier LA, Fortune F. Genital ulcer severity score and genital health quality of life in Behcet’s disease. Orphanet J Rare Dis. 2015;10:117.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Seyahi E, Cakmak OS, Tutar B, Arslan C, Dikici AS, Sut N, et al. Clinical and ultrasonographic evaluation of lower-extremity vein thrombosis in Behcet syndrome: an observational study. Medicine (Baltimore). 2015;94(44):e1899.CrossRefGoogle Scholar
  51. 51.
    Alibaz-Oner F, Aldag B, Aldag M, Unal AU, Mutiş A, Toptas T, et al. Post-thrombotic syndrome and venous disease-specific quality of life in patients with vascular Behçet’s disease. J Vasc Surg Venous Lymphat Disord. 2016;4(3):301–6.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Mioshi E, Dawson K, Mitchell J, Arnold R, Hodges JR. The Addenbrooke’s Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening. Int J Geriatr Psychiatry. 2006;21:1078–85.PubMedCrossRefGoogle Scholar
  53. 53.
    Siva A, Kantarci OH, Saip S, Altintas A, Hamuryudan V, Islak C, et al. Behçet’s disease: diagnostic and prognostic aspects of neurologic involvement. J Neurol. 2001;248:95–103.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Cheon JH, Han DS, Park JY, Ye BD, Jung SA, Park YS, et al. Development, validation, and responsiveness of a novel disease activity index for intestinal Behcet’s disease. Inflamm Bowel Dis. 2011;17:605–13.PubMedCrossRefGoogle Scholar
  55. 55.
    Best WR, Becktel JM, Singleton JW, Kern FJ. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology. 1976;70(3):439–44.PubMedCrossRefGoogle Scholar
  56. 56.
    Moses Alder N, Fisher M, Yazici Y. Behçet’s syndrome patients have high levels of functional disability, fatigue and pain as measured by a Multi-dimensional Health Assessment Questionnaire (MDHAQ). Clin Exp Rheumatol. 2008;26(Suppl 50):S110–3.PubMedGoogle Scholar
  57. 57.
    Mumcu G, Lehimci F, Fidan O, Guk H, Alpar U, Unal AU, et al. The assessment of work productivity and activity impairment in Behcet’s disease. Turk J Med Sci. 2017;47(2):535–41.PubMedCrossRefGoogle Scholar
  58. 58.
    Serin N, Ozguler Y, Esatoglu SN, Hamuryudan V, Hatemi G. Work productivity is impaired in patients with Behçet’s syndrome. Arthritis Rheumatol. 2018;70(suppl 10).Google Scholar
  59. 59.
    Yankouskaya A, Boughey A, McCagh J, Neal A, de Bezenac C, Davies SJ. Illness perception mediates the relationship between the severity of symptoms and perceived health status in patients with Behcet disease. J Clin Rheumatol. 2018;  https://doi.org/10.1097/RHU.0000000000000872.
  60. 60.
    Grayson PC, Amudala NA, McAlear CA, Leduc RL, Shereff D, Richesson R, et al. Causal attributions about disease onset and relapse in patients with systemic vasculitis. J Rheumatol. 2014;41(5):923–30.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Mumcu G, Yağar F, Alibaz-Öner F, İnanç N, Direskeneli H, Ergun T. Does illness perception associate with disease symptoms in Behçet’s disease? Intern Emerg Med. 2018;  https://doi.org/10.1007/s11739-018-1983-y.PubMedCrossRefGoogle Scholar
  62. 62.
    Bodur H, Borman P, Ozdemir Y, Atan C, Kural G. Quality of life and life satisfaction in patients with Behçet’s disease: relationship with disease activity. Clin Rheumatol. 2006;25:329–33.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Gilworth G, Chamberlain MA, Bhakta B, Haskard D, Silman A, Tennant A. Development of the Behçet’s disease quality of life, a quality of life measure specific to Behçet’s disease. J Rheumatol. 2004;31:931–7.PubMedGoogle Scholar
  64. 64.
    Hatemi G, Ozguler Y, Direskeneli H, Mahr A, Gul A, Levi V, et al. Current status, goals, and research agenda for outcome measures development in Behçet syndrome: report from OMERACT 2014. J Rheumatol. 2015;42(12):2436–41.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Hatemi G, Meara A, Ozguler Y, Direskeneli H, Mahr A, Easley E, et al. Developing a core set of outcome measures for Behçet disease: report from OMERACT 2016. J Rheumatol. 2017;44:1750–3.PubMedCrossRefGoogle Scholar
  66. 66.
    Ozguler Y, Merkel PA, Gurcan M, Bocage C, Eriksen W, Hatemi G, et al. Patients’experiences with Behçet’s syndrome: Structured interviews among patients with different types of organ involvement. Clin Exp Rheum. 2019; (in press).Google Scholar
  67. 67.
    Hatemi G, Meara A, Ozguler Y, Direskeneli H, Mahr A, Shea B, et al. The OMERACT Core Domain Set for clinical trials in Behçet’s syndrome. Arthritis Rheumatol. 2018;70 (suppl 10).Google Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Gonca Mumcu
    • 1
  • Yusuf Yazici
    • 2
  • Gulen Hatemi
    • 3
  1. 1.Marmara University, Faculty of Health Sciences, Department of Health ManagementIstanbulTurkey
  2. 2.School of MedicineNew York UniversityNew YorkUSA
  3. 3.Department of Internal Medicine, Division of RheumatologyIstanbul University-Cerrahpasa, School of MedicineIstanbulTurkey

Personalised recommendations